Iovance Biotherapeutics (IOVA) Reports In-Line Q4 EPS

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. QGEN
5. NDAQ
6. QS
7. BRO
8. BFH
9. SAP
10. AVEX

Go back to Iovance Biotherapeutics (IOVA) Reports In-Line Q4 EPS

Iovance Biotherapeutics (IOVA) Granted Fast Track Designation for LN-145 for Cervical Cancer

February 26, 2019 7:19 AM EST

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for LN-145 for the treatment of patients with recurrent, metastatic or persistent cervical cancer who have progressed while on or after chemotherapy. LN-145 is the Companys adoptive cell therapy produced using its proprietary TIL manufacturing technology.

We are pleased to have received Fast Track designation for LN-145 for the... More